# Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139

> **NCT02362464** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 14 (actual)

## Conditions studied

- Prostatic Neoplasms
- Neoplasms of Prostate
- Prostate Cancer
- Cancer Of Prostate
- Stage D0 Prostate Cancer

## Interventions

- **BIOLOGICAL:** Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine

## Key facts

- **NCT ID:** NCT02362464
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-12
- **Primary completion:** 2022-03-25
- **Final completion:** 2022-03-25
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2024-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02362464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02362464, "Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02362464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*